Infinity Pharmaceuticals, Inc. (INFI)
(Delayed Data from NSDQ)
$1.71 USD
+0.06 (3.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
+0.06 (3.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study
by Zacks Equity Research
CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.
Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down
by Zacks Equity Research
Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.
Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Infinity Pharmaceuticals (INFI) stock based on the movements in the options market lately.
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.
Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
Is the Options Market Predicting a Spike in Infinity (INFI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -6.25% and 11.80%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Momentum Investors Will Love Infinity Pharmaceuticals (INFI)
by Zacks Equity Research
Does Infinity Pharmaceuticals (INFI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
by Zacks Equity Research
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
Implied Volatility Surging for Infinity (INFI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.
Infinity (INFI) Provides Data on Eganelisib in Urothelial Cancer
by Zacks Equity Research
Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -6.67% and 130.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer
by Zacks Equity Research
Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU
by Zacks Equity Research
The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Infinity (INFI) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity (INFI) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -111.11% and 74.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?